Dexin Zhang
Ying Cui2- 1Department of Surgery, Hebei Medical University, Shijiazhuang, China
- 2Department of Neurology, Tangshan Gongren Hospital, Tangshan, China
- 3Department of Histology and Embryology, North China University of Science and Technology, Tangshan, China
- 4Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- 5Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, China
Background: Orexin-A (OXA) is a polypeptide produced in the hypothalamus, which binds to specific receptors and exerts multiple physiological effects. Autophagy plays a vital role in early brain injury (EBI) after intracerebral hemorrhage (ICH). However, the relationship between OXA and autophagy after ICH has not been confirmed.
Methods: In this study, the protective role of OXA was investigated in a model of hemin-induced injury in PC12 cells and blood-injection ICH model in rats, and its potential molecular mechanism was clarified. Neurobehavioral tests, brain water content, and pathologic morphology were assessed after ICH. Cell survival rate was determined using Cell Counting Kit-8 (CCK-8), while apoptosis was detected using flow cytometry. The autophagy protein LC3 that was originally identified as microtubule-associated protein 1 light 3 was evaluated by immunohistochemistry. The ultrastructural changes of cells following ICH were observed by transmission electron microscopy. Western blotting was performed to determine the expression levels of LC3, p62/SQSTM1 (p62), phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2), total extracellular signal-regulated kinase 1/2 (t-ERK1/2), mammalian target of rapamycin (mTOR), and phosphorylated mammalian target of rapamycin (p-mTOR).
Results: OXA treatment significantly improved neurofunctional outcomes, reduced brain edema, and alleviated neuronal apoptosis. OXA administration upregulated p-mTOR and p62, while it downregulated p-ERK1/2 and LC3; this effect was reversed by the orexin receptor 1 (OXR1) antagonist SB-334867.
Conclusions: This study demonstrates that OXA suppresses autophagy via the OXR1-mediated ERK/mTOR signaling pathway to exert neuroprotective effects, and it might provide a novel therapeutic approach in patients suffering from ICH.
1 Introduction
Intracerebral hemorrhage (ICH) is the leading cause of disability and death all over the world (Appelboom et al., 2012), affecting approximately 2 million individuals per year (Kang and Yao, 2019), and it causes an enormous economic burden on families and society (Benjamin et al., 2017). Brain injury following ICH includes primary injury caused by direct compression of the hematoma and secondary changes caused by various reasons such as inflammation, oxidative stress, mitochondrial dysfunction, and neuronal death (Kim-Han et al., 2006; Mracsko and Veltkamp, 2014; Hu et al., 2016; Zhao et al., 2018), among which the secondary changes is an important factor that affects prognosis of patients with ICH (Zhao et al., 2015). Therefore, prevention and treatment of secondary brain injury (SBI) occurrence and development after ICH is very valuable (Dang et al., 2017).
Autophagy is a basic biological procedure through which eukaryotic cells degrade organelles and misfolded, or damaged proteins to maintain normal cellular function (Boya et al., 2013; Füllgrabe et al., 2013; Kim et al., 2013). Under the circumstances of oxidative stress and inadequate nutrition, autophagy primarily functions as a cell survival adaptation mechanism (Bennett et al., 2010; Wellnitz and Taegtmeyer, 2010; Wirawan et al., 2012). It has been shown that autophagy plays a critical function in many central nervous system (CNS) diseases, including neurodegenerative diseases (Salminen et al., 2013; Gan-Or et al., 2015) and cerebral ischemia (Kotoda et al., 2018; Yu et al., 2019). Previous studies, including those on neonatal hypoxia–ischemia brain injury (Carloni et al., 2008) and subarachnoid hemorrhage (SAH) (Jing et al., 2012), have suggested that autophagy is an important protective process. Whereas, in other studies, autophagy has been shown to cause apoptosis in models of cerebral ischemia (Rami et al., 2008), traumatic brain injury (Cui et al., 2015) and ICH (Duan et al., 2017). Therefore, the role of autophagy in nerve cells may depend on the injury model and specific the cellular context (Li H. et al., 2018; Zhao et al., 2021). As reported in a previous study, the activation of autophagy following ICH plays a critical role in the mechanism of brain tissue damage (Shen et al., 2016).
Orexins (OXs) are polypeptides primarily produced by neurons in the lateral hypothalamus (Barinaga, 1998; Feng et al., 2014). Orexins exist in two forms—orexin A (OXA) and orexin B (OXB), which play a wide range of roles, including feeding, analgesic effects, sleep/wakefulness, sleep-pain interplay, energy metabolism, and drug addiction (Mohammad Ahmadi Soleimani et al., 2015; Ahmadi-Soleimani et al., 2020; Li et al., 2020), by binding to two G-protein-coupled receptors (GPCRs), orexin receptor 1 (OXR1), and orexin receptor 2 (OXR2) (Wang et al., 2018). Although the functions of OXs are diverse, one of the main functions of OXs is protection, particularly in neurological disorders. It has been reported that exogenous OXA administration has a neuroprotective effect on dopaminergic neurons in Parkinson’s disease (Drouot et al., 2003). Other studies on rat model of cerebral ischemia have shown similar neuroprotective effects (Kitamura et al., 2010).
Research has confirmed the relationship between the protective role of OXA and autophagy in models of cerebral ischemia–reperfusion injury (CIRI) or middle cerebral artery occlusion (MCAO). However, relatively few studies have assessed the relationship between OXA and autophagy in ICH. In this research, we hypothesized that OXA could exert a protective role on ICH-induced brain injury through inhibiting autophagy. Subsequently, the in vivo and in vitro model of ICH was developed, and a variety of experiments were conducted to verify our hypothesis and to provide new ideas for the treatment strategy of ICH.
2 Materials and methods
2.1 The animals
A total of 100 healthy adult male Sprague-Dawley (SD) rats (250–300 g, 10–12 weeks) were purchased from BEIJING HUAFUKANG BIOSCIENCE Co., Ltd. (Beijing, China) and housed in a standard environment (temperature of 25°C, humidity of 55%, and 12 h light/dark cycles) with free access food and water. All experimental schemes were sanctioned by the Laboratory Animal Ethical and Welfare Committee of North China University of Science and Technology (approval number: SQ 2022170) and followed the National Institutes of Health (NIH) Guide on Laboratory Animal Care and Use. People strictly follow the “3R” principle (Replace, Reduce, Refine) to carry out this operation.
2.2 Cell culture
The PC12 cell line of the rat adrenal medulla pheochromocytoma, purchased from the Cell Resource Center of the Chinese Academy of Sciences (Shanghai, China), were cultured in Dulbecco’s modified Eagle’s medium (Gibco; CA, USA) with 10% fetal bovine serum (Bovogen; Melbourne, VIC, AUS) and 1% penicillin/streptomycin antibiotics (Gibco; CA, USA) at 37°C in a humid environment containing 5% CO2 and 95% air. After being grown to the appropriate concentration, the cells were seeded into 96-well plates, 60 mm dishes, and 100 mm dishes for subsequent experiments.
2.3 Intracerebral hemorrhage (ICH) models
2.3.1 ICH model in vitro
As previously described (Zhou et al., 2017), an in vitro model of ICH was established by treating PC12 cells with hemin. Briefly, when PC12 cells were normally cultured to 70–80% confluency, they were stimulated with hemin for a period of time for construction of the in vitro model of ICH.
2.3.2 ICH model in vivo
According to the previous study (Yang et al., 2021), autologous blood from the tail artery was injected into the right basal ganglia to establish an in vivo ICH model. Briefly, an intraperitoneal injection of 10% chloral hydrate was used to anesthetize the animals, and then, they were fixed by a stereotaxic instrument (Stoelting; Kiel, WI, USA). A total of 50 μL autologous blood from the tail artery of the rat was infused into the right basal ganglia via a 26-gauge needle at a speed of 3.33 μL/min using a micro-infusion pump (Harvard Apparatus Inc., South Natick, MA, USA) at the following coordinates relative to bregma: 0.2 mm anterior, 3.5 mm right lateral, and 5.5 mm deep. Rats in the sham group only received a needle insertion without injection. In order to prevent backflow, the needle remained in place for an additional 5 min after intracerebral infusion. ICH rats were received intracerebroventricular injection (2 μL/min) of OXA drug solution (30 μg/kg, Phoenix Pharmaceuticals; Belmont, CA, USA) or vehicle (Dimethyl sulfoxide) 1 h after ICH induction (coordinates: 0.8 mm posterior and 1.6 mm lateral of bregma and at a depth of 4.0 mm).
2.4 Study design
2.4.1 Experiment 1: Time-course changes of LC3 and p62
Twenty-seven rats (30 rats suffered to the surgery, 27 rats survived) were randomly and evenly allotted to 9 groups of 3 rats each, namely, sham group, ICH 12 h group, ICH 24 h group, ICH 48 h group, ICH 3 d group, ICH 5 d group, ICH 7 d group, ICH 14 d group, ICH 28 d group. The expression of autophagy-related proteins (including LC3B and p62) in the perihematomal tissue was detected by Western blot (WB) analysis.
2.4.2 Experiment 2: Evaluate protective effects of OXA
Sixty-four rats (70 rats experienced the operation, 64 rats survived) were randomly assigned into 4 groups (16 rats per group): sham group, ICH group, ICH + vehicle (dimethylsulfoxide, DMSO) group, ICH + OXA 30 μg/kg group. Modified Neurological Severity Score (mNSS) and corner turn test (n = 7) were performed at 48 h after ICH to evaluate the neurofunction. After the tests, rat brains were harvested for brain water content (BWC) measurements (n = 7). Then, the other rats were taken to perform H&E, Nissl and immunohistochemistry (IHC) staining (n = 3), transmission electron microscopy (n = 3) and WB (n = 3). All rats were sacrificed by deeply anesthetized with an i.p. of 10% chloral hydrate, and then were decapitated. The animal carcasses were frozen and returned to the laboratory animal center for unified harmless treatment.
2.4.3 Experiment 3: Mechanisms of the protective effect of OXA
This part of the experiment was carried out at the cellular level. The cells were randomly divided into seven groups: Control (untreated) group, Hemin group, Hemin + vehicle (DMSO) group, Hemin + OXA (100 nM) group, Hemin + PD98059 group, Hemin + OXA (100 nM) + Rapamycin group, Hemin + OXA (100 nM) + SB334867 group. All groups in this experiment were taken to perform Cell Counting Kit-8 (CCK-8), Western blotting and flow cytometric apoptosis assay to confirm the mechanisms of the protective effect of OXA. All assays were repeated at least three times.
2.5 Evaluation of neurological dysfunction
Neurological deficits in rats at 2 days following ICH were evaluated using the modified neurologic severity score (mNSS). The severity score is graded on a scale of 0–18, in which 13–18 indicates severe injury; 7–12 represents moderate injury; and 1–6 expresses mild injury. The higher the score, the more severe the injury. In addition, the short-term neurological outcomes after ICH were also assessed by the corner turn test, as previously described (Xi et al., 2018). The results are expressed as the percentage of left turns to all turns. All tests were assessed by two trained investigators without knowing of the groups.
2.6 Brain water content measurement
Brain water content was determined using the wet/dry method, as previously described (Manaenko et al., 2011). In brief, at 48 h after ICH, the rats were decapitated after being deeply anesthetized. Brains were completely removed and weighed immediately to obtain wet weight, and they were desiccated at 105°C for 48 h to acquire dry weight. The percentage of BWC was determined as (wet weight-dry weight)/wet weight × 100%.
2.7 H&E and Nissl staining
After being deeply anesthetized, rats were sequentially injected with physiological saline and 4% paraformaldehyde through the heart. The brain tissues were isolated and fixed in 4% paraformaldehyde for 48 h, dehydrated with gradient alcohol, soaked in wax, embedded in paraffin, and then cut into 5 μm thick coronal section. H&E and Nissl staining were performed as previously described (Ning et al., 2019). The slides were mounted using neutral gum and observed under an optical microscope (BX51, Olympus, Tokyo, Japan).
2.8 Immunohistochemistry
Briefly, 5 μm thick brain tissue sections were prepared, as described above. Immunohistochemical staining was carried out in accordance with the instructions of immunohistochemistry kit (ZSJQ-BIO, Beijing, China). In brief, brain tissue slices were dewaxed and hydrated, and then citrate buffer was added to perform heat-induced antigen retrieval for 10 min, and then cooled to room temperature naturally. The slices were treated with 3% hydrogen peroxide to inactivate endogenous peroxidase at 25°C for 5 min. Rabbit anti-microtubule-associated protein light chain-3 polyclonal antibodies (GeneTex; Irvine, CA, USA; 1:50 dilution) were added, and then incubated overnight at 4°C; and subsequently incubated with horseradish peroxidase- (HRP) conjugated second antibody for 60 min, and then colored by diaminobenzidine (DAB). The sections were observed under an optical microscope at 400 × magnification and photographed.
2.9 Transmission electron microscopy
After anesthesia, rats were transcardially injected with saline, and then replaced with 4% paraformaldehyde and 2.5% glutaraldehyde. The brain tissue was completely removed and fixed in 2.5% glutaraldehyde at 4°C for 24 h, and then fixed with 1% osmium tetroxide for 90 min. After dehydration with graded alcohol, the tissues were permeated with propylene oxide and embedded in epoxy resin. Ultrathin sections were prepared and stained with 4% uranyl acetate for 20 min, and then stained with lead citrate for 5 min. The sections were observed using transmission electron microscopy (Hitachi, Tokyo, Japan).
2.10 Cell-viability assay
According to the manufacturer’s instructions, the CCK-8 kit was used to determine the viability of PC12 cells. PC12 cells were seeded into 96-well plates at an initial density of 1 × 104 per well and cultured for 24 h. The intervention of cells was performed according to the experimental requirements. After intervention, a total of 10 μL volume CCK-8 reagent was added each well and incubated for 1 h. A microplate reader was used to measure the optical density (OD value) of each well at 450 nm wavelength. All assays were repeated at least three times. Cell viability was calculated using the following formula: cell viability (%) = (OD value of experimental group/average OD value of control group) × 100%.
2.11 Flow cytometric analysis of apoptosis
In accordance with the manufacturer’s instructions, flow cytometry was used to detect apoptosis in PC12 cells after staining with the Annexin V-FITC apoptosis detection kit (Beyotime, Shanghai, China). PC12 cells were planted into 60 mm dishes at an initial density of 2 × 105 and normally cultured to 80–90% confluency. After different treatments, the cells were collected and washed with PBS. Thereafter, the cells were resuspended in 195 μL 1 × binding buffer at a density of 1 × 105/ml and stained with 5 μL Annexin V-FITC and 10 μL propidium iodide for 15 min at 25°C in the dark. After reaction, the treated cells were analyzed by flow cytometer (Beckman Coulter, USA) within 1 h. All assays were repeated at least three times.
2.12 Western blot analysis
After anesthesia, the rats were decapitated and the perihematomal brain tissues were gathered. The perihematomal brain tissues and PC12 cells were lysed for 30 min in precooled RIPA lysis buffer (Beyotime, Shanghai, China) including proteinase and phosphatase inhibitors. After centrifugation at 12,000 rpm for 15 min at 4°C, the protein concentration in supernatant was determined by the BCA protein assay kit (Beyotime, Shanghai, China). Equal amounts of protein (50μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 6, 10, or 12% polyacrylamide gels and transferred onto 0.22 μm Hybond-polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% non-fat milk in Tris-buffered saline containing 0.05% Tween 20 (TBST, pH 7.4) for 90 min, and then incubated overnight at 4°C with the appropriately diluted primary antibodies: rabbit anti-p-ERK1/2 (1:1,000 dilution; HuaAn Biotechnology Co., Ltd., Hangzhou, China), rabbit anti-t-ERK1/2 (1:1,000 dilution; HuaAn Biotechnology Co., Ltd., Hangzhou, China), rabbit anti-p-mTOR (1:1,000 dilution; Arigo; Hsinchu, Taiwan, China), rabbit anti-mTOR (1:1,000 dilution; HuaAn Biotechnology Co., Ltd., Hangzhou, China), rabbit anti-LC3B (1:1,000 dilution; GeneTex; Irvine, CA, USA), rabbit anti-p62 (1:1,000 dilution; MBL; Nagoya, Japan), mouse anti-GAPDH (1:1,000 dilution; ABclonal; Wuhan, China), and rabbit anti-β-actin (1:100,000 dilution; ABclonal; Wuhan, China). After washing, the membranes were incubated with the corresponding HRP-conjugated secondary antibodies (1:5,000 dilution; ABclonal; Wuhan, China) for 120 min at 25°C. Blots were visualized with an enhanced chemiluminescence detection kit (ECL; Beyotime, Shanghai, China) and quantified with Image J software.
2.13 Statistical analysis
All data are expressed as mean ± standard deviation (mean ± SD). SPSS 25.0 statistical software was used for data analysis, and GraphPad Prism 8.0 software was used to make statistical charts. The differences among multiple groups were determined with one-way ANOVA analysis, followed by post hoc Tukey test, and the comparison between two groups was performed by independent samples t-test. For all comparisons, P < 0.05 was considered statistically significant.
3 Results
3.1 OXA attenuates secondary brain injury (SBI) after ICH in vivo
In order to elucidate the protective effect of OXA, autologous blood injection was performed to establish an ICH model in vivo. To evaluate the effect of OXA treatment on early brain injury (EBI) at 48 h after ICH, mNSS and corner turn test were used to assess neurological dysfunctions, and the wet/dry method was used to determine BWC, and H&E and Nissl staining were used to evaluate brain damage.
The findings showed that the mNSS scores were significantly increased in the 48 h post-ICH and vehicle groups compared with the sham group. There was a significant difference between the OXA and vehicle groups, suggesting that OXA had a positive effect in reducing neurologic impairments (Figure 1A). In the corner turn test, the percentage of left turns in the ICH and vehicle groups was significantly lower than in the sham group, while the percentage of left turns in the OXA treatment group was significantly higher than in the ICH-injury group (Figure 1B). Additionally, the ICH and vehicle groups showed significant increases in the BWC, which was attenuated by OXA treatment (Figure 1C). The results of H&E and Nissl staining revealed that relative to the sham group, neurons in the 48 h post-ICH and vehicle group had a disordered arrangement showing karyopyknosis and cytoplasmic loosening, and the nucleolus had disappeared. In contrast, treatment with OXA alleviate the neuronal damage after ICH (Figures 1D, E). Taken together, these data indicate that OXA has neuroprotective effects after ICH.
Figure 1. Orexin-A alleviates early brain injury following ICH in vivo. (A) Modified neurological severity scores (mNSS) and (B) corner turn test showed that neurological function was significantly impaired after ICH, and OXA treatment significantly improved outcomes. (C) Water content of brain tissues in each group. ***p < 0.001 and ****p < 0.0001 vs. the sham group; NS, non-significant different compared to the ICH group. ##p < 0.01, ###p < 0.001 and ####p < 0.0001 vs. the ICH group. (D,E) Representative images of H&E and Nissl staining in the perihematomal brain tissues region. Scale bar, 50 μm.
3.2 Autophagy is activated after ICH
In order to observe autophagy in the ICH injury model in vivo, the expression of autophagy-related proteins (including LC3B and p62) in the perihematomal tissue at different time points after ICH was detected by WB analysis. The results demonstrated that relative to the sham group, the ratio of LC3B-II/LC3B-I after ICH was markedly increased at 12 h, and it peaked at day 2, and decreased markedly at day 14. In contrast, the protein expression level of p62 showed an opposite trend at the same time points (Figure 2). Based on these results, 48 h after ICH were considered the optimal time point for subsequent experiments.
Figure 2. The expression changes of autophagy-related proteins (LC3B and p62) at different time points after ICH. (A) Representative western blot images of LC3B and p62. (B,C) Quantitative analysis of LC3B and p62 in each group. *p < 0.05, ***p < 0.001 and ****p < 0.0001 vs. the sham group; NS, non-significant different compared to the sham group.
3.3 OXA inhibits activation of autophagy
A previous study demonstrated that inhibition of autophagy can reduce brain damage after ICH (Yuan et al., 2017). After verifying that ICH can activate autophagy and OXA has a neuroprotective role in ICH injury, we speculated that OXA may play a neuroprotective role by regulating autophagy activity. A variety of methods were used to monitor autophagy, such as immunohistochemistry, Western blotting etc.
To identify whether OXA could inhabit autophagy in vivo, we used Western blotting to analyze the expression of autophagy-related proteins in the perihematomal region after ICH. As shown in Figure 3A, ICH upregulated the ratio of LC3B-II/LC3B-I and downregulated the level of p62. On the contrary, administration of OXA significantly decreased the ratio of LC3B-II/LC3B-I and increased the p62 level. Consist with the Western blotting results, the immunohistochemistry staining had similar trends (Figure 3B). In addition, electron microscopy is believed to be the most sensitive and precise method of monitoring autophagy, which distinctly reveals the presence of autophagosomes and autolysosomes in the area around the hematoma after ICH. In contrast, cells in the same area of sham rats contained few vacuoles, and intact nuclei and mitochondrial crista were observed (Figure 3C). After administration of OXA, we observed that the double-membrane structures were decreased and swollen mitochondria were scattered throughout the cytoplasm, which indicates alleviation of cellular damage.
Figure 3. Orexin-A inhibits ICH-induced autophagy activation. (A) Western blot images of LC3B and p62 and results of quantitative analysis in the perihematomal area of rats after ICH. (B) Representative immunohistochemical staining images of LC3B in each group. Positive cells were stained brown. Scale bar, 20 μm. (C) Ultrastructural observation of perihematomal brain tissue after ICH by transmission electron microscopy, black arrows represent autophagosome. Scale bar, 1 μm. ****p < 0.0001 vs. the sham group; NS, non-significant different compared to the sham group; ###p < 0.001, ####p < 0.0001 vs. the ICH group.
3.4 The neuroprotective effect of OXA is mediated by inhibition of autophagy via the ERK/mTOR signaling pathway
In order to verify the above experimental results and elucidate the molecular mechanism of OXA’s neuroprotective effect, we further explored at the cellular level. We used PC12 cells to simulate neurons in vitro to exclude the interference between various types of cells in the brain tissue in vivo and adopted hemin-induced injury of PC12 cells as an in vitro model of ICH.
3.4.1 OXA relieves hemin-induced injury of PC12 cells in vitro
Firstly, to ascertain the optimal concentration and time for the toxic effect of hemin treatment on PC12 cells, cells were treated with different concentrations of hemin for 3, 6, 12, and 24 h, and the cell viability was evaluated by CCK-8. The results showed that the cell survival rate was declined in a concentration-dependent manner with the prolongation of hemin treatment time (Figure 4A). Then, we selected 50 μM as the optimal dose for hemin treatment, and treated the PC12 cells for 12 h, and then, we used the same dose in subsequent experiments.
Figure 4. Orexin-A relieves hemin-induced PC12 cells injury in vitro. (A) Survival curve of hemin-induced PC12 cells injury. (B) Effects of treatment with various concentrations of OXA on the hemin-induced decrease in the viability of PC12 cells. ***p < 0.001 vs. non-treated group; **p < 0.01 and ****p < 0.0001 vs. hemin-treated group; NS, no- significant difference between the two groups. (C) OXA attenuates the hemin-induced decrease in cell viability. (D) OXA inhibited hemin-induced apoptosis. PC12 cells were divided into four groups, the effects of OXA on apoptosis were detected by flow cytometric, and representative FCM plots are shown. (E) Quantified results of the flow cytometric analysis. ***p < 0.001 and ****p < 0.0001 vs. the control group; NS, non-significant different compared to the hemin group. &&p < 0.01 and &&&p < 0.001 vs. the hemin group.
Secondly, to determine the optimal concentration of OXA to protect PC12 cells against hemin-induced neurotoxicity, cells were pre-treated with 10, 100, and 1,000 nM OXA for 6 h and then incubated with 50 μM hemin for 12 h, and the cell viability was evaluated by CCK-8. The results demonstrated that the cell survival rates were significantly higher in the 10, 100, and 1,000 nM pre-treatment groups than in the group treated with hemin alone (Figure 4B). Moreover, cell viability in the group pre-treated with 100 nM OXA was almost as high as that in the group pre-treated with 1,000 nM OXA (Figure 4B). Based on these results, treatment with 100 nM OXA for 6 h was considered optimal and was performed in subsequent experiments.
Thirdly, to confirm the neuroprotective effect of OXA in vitro, PC12 cells were pre-treated with 100 nM OXA for 6 h and then 50 μM hemin was added for 12 h. Subsequently, PC12 cells viability was evaluated using the CCK-8 assay, and cell apoptosis was analyzed by the flow cytometry method. The results demonstrated that the apoptosis ratio was significantly increased in the hemin group compared with the control group. In contrast, the apoptosis rate was significantly lower in the OXA group than in the group treated with hemin (Figures 4D, E). In line with the flow cytometry results, CCK-8 assays also observed the same trend (Figure 4C). These results suggest that OXA relieves hemin-induced injury of PC12 cells in vitro.
3.4.2 Hemin-induced injury triggers autophagy, and OXA inhibits autophagy
To ascertain the above results in vitro, we further investigated the expression levels of LC3B and p62 in PC12 cells at 3, 6, and 12 h after hemin treatment. The results of Western blotting showed that with an increase in the hemin treatment time, the ratio of LC3B-II/LC3B-I was increased and the content of p62 was progressively decreased, showing a time-dependent effect (Figure 5A).
Figure 5. Hemin-induced injury triggers autophagy, and OXA inhibits autophagy. (A) The expression changes of autophagy-related proteins (LC3B and p62) at different time points after hemin-induced injury. (B) Western blot images of LC3B and p62 and results of quantitative analysis in each group of PC12 cells. ***p < 0.001 and ####p < 0.0001 vs. the control group; NS, non-significant different compared to the control group. ###p < 0.001 vs. the hemin group.
To observe the role of OXA in autophagy in an in vitro model of ICH, the Western blotting was used to determine the ratio of LC3B-II/LC3B-I and the p62 level. The results showed that compared with the control group, the ratio of LC3B-II/LC3B-I were significantly elevated and the level of p62 was decreased after hemin-induced injury, whereas the OXA-treated group obtained the opposite results (Figure 5B).
3.4.3 Rapamycin stimulates autophagy and reversed the protective effect of OXA
To further investigate the relationship between autophagy and the protective effect of OXA, PC12 cells were pretreated with rapamycin (an allosteric inhibitor of the mammalian target of rapamycin complex 1; Cayman Chemical; Ann Arbor, MI, USA) before the addition of OXA. The autophagy-related protein expression was detected by Western blotting. OXA could significantly increase the expression levels of p62, and decrease the ratio of LC3B-II/LC3B-I, while partly blocked with rapamycin pretreatment (Figure 6A). The CCK-8 assay demonstrated that pretreated with rapamycin could decrease the cell viability of PC12, compared with OXA treatment alone (Figure 6B). Flow cytometry for apoptosis showed similar results (Figures 6C, D). In summary, OXA may exert a protective effect by regulating autophagy activity.
Figure 6. Rapamycin stimulates autophagy and reverses the neuroprotective effect of OXA. (A) Western blot images of LC3B and p62 and results of quantitative analysis in each group. (B) OXA attenuates the hemin-induced decrease in cell viability, while aggravated it after rapamycin administration. (C) Representative FCM plots of Annexin V-FITC apoptosis detection assay showed that autophagy activator increased apoptosis rate, and reversed the neuroprotective effect of OXA. (D) Quantified results of the flow cytometric analysis. ***p < 0.001 vs. the control group; *p < 0.05, ****p < 0.0001 vs. the hemin group; #p < 0.05, ####p < 0.0001 vs. the hemin + OXA group.
3.4.4 OXA inhibits autophagy via ERK and mTOR signaling
Kim et al. (2014) and Laplante and Sabatini (2012) have reported that the ERK and mTOR signaling pathway can regulate autophagy. Thus, the present research investigated whether OXA exerts neuroprotective effects through the ERK/mTOR signaling pathway. Firstly, after treatment with hemin and OXA, the protein expression levels of p-ERK1/2/t-ERK1/2/p-mTOR were detected by Western blotting. The results showed that the level of p-mTOR protein was decreased with the aggravation of hemin-induced injury, while the level of p-ERK1/2 was increased (Figure 7A). As shown in Figure 7B, relative to the hemin treatment group, the expression of p-ERK1/2 remarkably downregulated after OXA treatment, whereas the expression of p-mTOR remarkably upregulated.
Figure 7. The neuroprotective effects of OXA are mediated via the ERK/mTOR signaling pathway. (A) Representative western blots of p-mTOR and p-ERK1/2 and results of quantitative analysis in PC12 cells treated with Hemin for 3, 6, and 12 h. (B) Western blot images of p-mTOR and p-ERK1/2 and results of quantitative analysis in each group. (C) Representative western blots of p-mTOR and p-ERK1/2 and results of quantitative analysis in PC12 cells treated with Hemin and PD98059. (D) Western blot images of LC3B and p62 and results of quantitative analysis in each group. **p < 0.01, ***p < 0.001 and ****p < 0.0001 vs. the control group; NS, non-significant different compared to the hemin group. ##p < 0.01, ###p < 0.001 and ####p < 0.0001 vs. the hemin group.
Next, we used PD98059, a non-competitive inhibitor of MAPK kinase or MEK kinase, to ascertain whether ERK is a critical factor of the upstream pathway of autophagy in hemin-induced injury. The results demonstrated that, relative to cells treated with hemin alone, pre-treated with PD98059 remarkably downregulated the expression of p-ERK1/2 and upregulated the expression of p-mTOR (Figure 7C). Meanwhile, PD98059 significantly downregulated the LC3B-II/LC3B-I ratio and upregulated the expression of p62 (Figure 7D). These results indicate that OXA plays a protective role by inhibiting autophagy via the ERK/mTOR signaling pathway.
3.5 OXA coupled with OXR1 protects against hemin-induced PC12 cells injury
The above findings have confirmed the protective effect and possible signaling pathway of OXA following ICH injury. In subsequent research, to further elucidate the neuroprotective of OXA, we pre-treated PC12 cells with the OXR1 antagonist SB334867. The CCK-8 assay was used to measure cell viability, and flow cytometry was used to detect apoptosis. The findings demonstrated that relative to the control group, the cell survival rate was remarkably decreased after hemin-induced injury. However, cell viability was significantly increased in the OXA group, relative to the hemin-treated group. When hemin-induced injury cells were subsequently treated with the combination of SB334867 and OXA, cell viability was significantly reduced compared with OXA treatment alone (Figure 8A). As expected, our apoptosis measurements were consistent with the results of cells viability. The apoptotic frequencies were 49.64% in the hemin-induced ICH models. After OXA treatment, the apoptosis rate was decreased to 36.33%. Likewise, following treatment with SB334867 and OXA, the apoptosis rate was increased by 4.57% compared with that following OXA treatment alone (Figures 8B, C). Western blotting results demonstrated that the ratio of LC3B-II/LC3B-I and the level of p-ERK1/2 was significantly downregulated, whereas the levels of p-mTOR and p62 were remarkably increased with OXA treatment (Figures 8D, E). The above functions of OXA were remarkably reversed by OXR1 antagonist (SB334867). These results confirmed that the neuroprotective role of OXA is dependent on the combination with OXR1.
Figure 8. The protective effect of OXA needs to be combined with OXR1. (A) OXA attenuates the hemin-induced decrease in cell viability, while aggravated it after SB334867 administration. (B) Representative FCM plots of Annexin V-FITC apoptosis detection assay showed that OXR1 inhibitor increased apoptosis rate, and reversed the neuroprotective effect of OXA. (C) Quantified results of the flow cytometric analysis. (D) Western blot images of LC3B and p62 and results of quantitative analysis in each group. (E) Representative western blots of p-mTOR and p-ERK1/2 and results of quantitative analysis in PC12 cells treated with OXA and SB334867. **p < 0.01 and ****p < 0.0001 vs. the control group; ##p < 0.01, ###p < 0.001 and ####p < 0.0001 vs. the hemin group; &p < 0.05, &&&p < 0.001 and &&&&p < 0.0001 vs. the hemin + OXA group.
4 Discussion
In this research, we attempted to elucidate the therapeutic potential of orexin A (OXA) in alleviating SBI following ICH. Our findings suggested that OXA has neuroprotective effects and can reduce EBI and neuronal death after ICH. Specifically, we observed that: (i) OXA improved neurological dysfunction and mitigated brain damage in a rat ICH model; (ii) OXA alleviated apoptosis in a hemin-induced injury model of PC12 cells; (iii) OXA inhibits activation of autophagy following ICH by binding to the OXR1 receptor; and (iv) the anti-autophagy roles of OXA may be related to the ERK/mTOR pathway.
Recent research has shown that the change in orexins and their receptors might be related to stroke incident. Reduced cerebrospinal fluid (CSF) OXA levels have been reported to occur in patients with SAH and ICH (Dohi et al., 2005, 2008). Based on these results, it can be concluded that the orexin system may play a critical role in the pathophysiology of ICH. Likewise, a continuous decline of OXA level in CSF and a rise of expression of OXR1 in the cortical region was discovered in patients with cerebral ischemia (Nakamachi et al., 2005), suggesting an involvement of the orexin system in an ischemic insult. Recently, the neuroprotective of OXA in nervous system disorders, especially in cerebrovascular diseases, have been verified. Exogenous OXA injection effectively reduced the range of infarction and significantly improved the neurological function in a CIRI model in mouse and rats (Kitamura et al., 2010; Harada et al., 2011). Xu et al. (2021) proved that OXA alleviates damage induced by oxygen–glucose deprivation/reoxygenation (OGD/R) or MCAO by inhibiting autophagy. Likewise, Yuan et al. (2011) confirmed that OXA injection remarkably improved the motor and cognitive functions of rats with CIRI. On the basis of these research, we hypothesized that OXA might have a similar neuroprotective role in ICH rats. By means of neurobehavioral tests including mNSS detection and corner turn test at 48 h following ICH, combined with determination of BWC, we ascertained that OXA could dramatically ameliorate the short-term neurological function. H&E and Nissl staining showed that treatment with OXA alleviated neuronal damage after ICH. Hemin-induced injury in PC12 cells were assessed using the CCK-8 assay and flow cytometry method. We determined the optimal dosage of OXA for the subsequent research studies and further confirmed that OXA relieves hemin-induced injury in PC12 cells in vitro.
Autophagy is a highly conserved cellular physiological process, in which misfolded or damaged proteins are isolated in double membrane structure referred to as autophagosomes, delivered to lysosomes, and digested by lysosomal hydrolases. It is a major pathway to remove senescent or damaged organelles and long-lived proteins in eukaryotic cells, and it plays a critical role in maintaining intracellular homeostasis and recycling cellular components. Recently research have been confirmed that autophagy is associated with many CNS disorders, including cerebral ischemia (Xu et al., 2021), trauma (Cui et al., 2015), SAH (Jiang et al., 2021), and ICH (Yuan et al., 2017). In our study, we confirmed that autophagy occurs in the brain after ICH. Results of Western blotting demonstrated that the ratio of LC3B-II/LC3B-I following ICH was dramatically increased at 12 h, and it peaked at day 2 and decreased remarkably at day 14. In contrast, the protein expression level of p62 showed an opposite trend at the same time points, which indicated stimulation of the autophagy response. Similar results were obtained in in vitro experiments. The results in these in vitro and in vivo ICH models are consistent with the observations of other laboratories (He et al., 2008; Chen et al., 2012), which further demonstrate that autophagy can be activated following ICH.
Apoptosis is one of the main programmed cell death pathways leading to secondary cell death around hematoma after ICH. Inhibition of apoptosis can reduce brain edema and tissue damage and improve functional prognosis after experimental ICH (Krafft et al., 2012). In addition, a programmed form of cell death has been identified and named as autophagic cell death, also known as type II programmed cell death (Ouyang et al., 2012). Recent studies have suggested that autophagic cell death occurs after ICH and inhibition of autophagy contributes to alleviate iron-induced brain injury (Chen et al., 2012). A clinical study has shown that the number of autophagic neurons in patients with ICH is related to the severity of neuronal dysfunction and blood volume (Wu et al., 2019). These data suggest autophagy plays a detrimental role in ICH. In our in vivo and in vitro experiments, by immunohistochemistry and Western blotting, we observed that OXA can inhibit the activation of autophagy. We confirmed the immunohistochemistry and Western blotting findings by the most sensitive and accurate transmission electron microscopy that is for determining whether cells are undergoing autophagy. When PC12 cells were co-treated with the autophagy activator rapamycin and OXA, we found that the neuroprotective roles of OXA were weakened. Thus, we presumed that the neuroprotective role of OXA may be achieved by suppressing autophagy.
Autophagy is accurately controlled by a variety of signaling pathways, such as PI3K/AKT/mTOR (Vergadi et al., 2017; Li W. D. et al., 2018), Ras/Raf/MEK/ERK1/2 etc. (Kyriakakis et al., 2017; Yiu et al., 2018). The PI3K/AKT pathway is the classical autophagy pathway. Meanwhile, mTOR, as a downstream effector of the PI3K (phosphatidylinositol 3-kinase)/PKB (protein kinase B) signaling pathway, also exerts a significant role in CNS apoptosis and autophagy (Wu et al., 2018). Multiple cellular pathophysiological processes, including autophagy, are regulated by extracellular signal-regulated kinase (ERK) (Wen et al., 2016). An enhanced activity of ERK1/2 has been reported to be closely related to the control of autophagy activation. Activation of the ERK1/2 signal pathway has also been reported to increase the expression of autophagy-related genes and proteins. To explore whether OXA could inhibit PC12 cells autophagy via mTOR/ERK1/2 signaling pathway in vitro, we analyzed p-mTOR and p-ERK1/2 expression after hemin-induced injury. We found that with aggravation of hemin-induced injury, the expression of p-ERK1/2 was gradually increased, but the mTOR level was gradually decreased. However, the expression of p-ERK1/2 was dramatically decreased and the expression of p-mTOR was significantly increased after OXA treatment. Then, we treated PC12 cells with hemin-induced injury using an ERK specific antagonist PD98059. We found that the ERK inhibitor remarkably suppressed the p-ERK1/2 and LC3B-II/LC3B-I expression levels, but it increased p-mTOR expression in PC12 cells after hemin-induced injury. These data indicated that OXA may inhibit autophagy to play neuroprotective effect through the ERK and mTOR pathway.
It has been reported that OXR1 and OXR2 might exert different effects. Scammell and Winrow (2011) demonstrated that OXR2 or non-competitive orexins inhibitors were effective in treating insomnia, suggesting that OXR2 may play a more important role. Irving observed an increase in the OXR1 gene expression in rats with cerebral ischemia (Irving et al., 2002), while OXR2 gene expression did not change significantly. In this present research, we found that the neuroprotective role of OXA was remarkably reversed by SB-334867. Therefore, we conclude that the role of these two receptors is different; OXR1 is more participated in the ERK/mTOR signaling pathway and mediates the neuroprotective role following ICH.
After ICH, nerve cells suffer secondary injury caused by various pathological processes, such as inflammation, autophagy, and oxidative stress (Zhang and Liu, 2020). On the basis of our results, we would like to suggest that OXA, a polypeptide that can improve neurological functional defects after ICH, is neuroprotective. In this regard, one possibility is that OXA can reduce the level of autophagy in tissues surrounding hemorrhagic lesions after ICH. There has been reported evidence indicating that OXA can significantly improve neurofunctional outcomes after ICH through alleviating neuroinflammation (Li et al., 2020). Thus, the neuroprotective effect of OXA might also be indirectly mediated to some extent by suppressing inflammasome activation or directly sequester inflammasomes via autophagy-lysosomal pathway. However, the mechanism of interaction between autophagy and inflammation needs to be further studied. In addition, although we have confirmed that OXR1 is more involved in the neuroprotective effects of OXA after ICH, the details of the different roles of the two receptors remain unclarified. Therefore, it will be critical to explore these mechanisms in future studies.
5 Conclusion
In summary, OXA exerts a neuroprotective role in ICH rats by inhibiting autophagy through the OXR1-mediated ERK/mTOR pathway, and it might provide a novel therapeutic approach in patients suffering from ICH. More studies are needed to validate our findings and provide more evidence for OXA to treat ICH in clinical practice.
Data availability statement
The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement
This animal study was reviewed and approved by the Laboratory Animal Ethical and Welfare Committee of North China University of Science and Technology.
Author contributions
JC was responsible for experimental design and revised the manuscript. DZ performed the experiments and wrote the manuscript. MZ and JW carried out the experiments and analyzed the data. YC, CL, and XZ prepared the figures. KW provided some technical supports. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the Natural Science Foundation of Hebei Province (Grant no. H2019105137).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ahmadi-Soleimani, S. M., Mianbandi, V., Azizi, H., Azhdari-Zarmehri, H., Ghaemi-Jandabi, M., Abbasi-Mazar, A., et al. (2020). Coregulation of sleep-pain physiological interplay by orexin system: An unprecedented review. Behav. Brain Res. 391:112650. doi: 10.1016/j.bbr.2020.112650
Appelboom, G., Hwang, B. Y., Bruce, S. S., Piazza, M. A., Kellner, C. P., Meyers, P. M., et al. (2012). Predicting outcome after arteriovenous malformation-associated intracerebral hemorrhage with the original ICH score. World Neurosurg. 78, 646–650. doi: 10.1016/j.wneu.2011.12.001
Barinaga, M. (1998). New appetite-boosting peptides found. Science 279:1134. doi: 10.1126/science.279.5354.1134
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., et al. (2017). Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation 135, e146–e603. doi: 10.1161/CIR.0000000000000485
Bennett, H. L., Fleming, J. T., O’Prey, J., Ryan, K. M., and Leung, H. Y. (2010). Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis. 1:e72. doi: 10.1038/cddis.2010.50
Boya, P., Reggiori, F., and Codogno, P. (2013). Emerging regulation and functions of autophagy. Nat. Cell Biol. 15, 713–720. doi: 10.1038/ncb2788
Carloni, S., Buonocore, G., and Balduini, W. (2008). Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol. Dis. 32, 329–339. doi: 10.1016/j.nbd.2008.07.022
Chen, C.-W., Chen, T.-Y., Tsai, K.-L., Lin, C.-L., Yokoyama, K. K., Lee, W.-S., et al. (2012). Inhibition of autophagy as a therapeutic strategy of iron-induced brain injury after hemorrhage. Autophagy 8, 1510–1520. doi: 10.4161/auto.21289
Cui, C. M., Gao, J. L., Cui, Y., Sun, L. Q., Wang, Y. C., Wang, K. J., et al. (2015). Chloroquine exerts neuroprotection following traumatic brain injury via suppression of inflammation and neuronal autophagic death. Mol. Med. Rep. 12, 2323–2328. doi: 10.3892/mmr.2015.3611
Dang, G., Yang, Y., Wu, G., Hua, Y., Keep, R. F., and Xi, G. (2017). Early erythrolysis in the hematoma after experimental intracerebral hemorrhage. Transl. Stroke Res. 8, 174–182. doi: 10.1007/s12975-016-0505-3
Dohi, K., Ripley, B., Fujiki, N., Ohtaki, H., Shioda, S., Aruga, T., et al. (2005). CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH). Peptides 26, 2339–2343. doi: 10.1016/j.peptides.2005.04.004
Dohi, K., Ripley, B., Fujiki, N., Ohtaki, H., Yamamoto, T., Goto, Y., et al. (2008). CSF orexin-A/hypocretin-1 concentrations in patients with intracerebral hemorrhage (ICH). Regul. Pept. 145, 60–64. doi: 10.1016/j.regpep.2007.08.005
Drouot, X., Moutereau, S., Nguyen, J. P., Lefaucheur, J. P., Créange, A., Remy, P., et al. (2003). Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61, 540–543. doi: 10.1212/01.wnl.0000078194.53210.48
Duan, X. C., Wang, W., Feng, D. X., Yin, J., Zuo, G., Chen, D. D., et al. (2017). Roles of autophagy and endoplasmic reticulum stress in intracerebral hemorrhage-induced secondary brain injury in rats. CNS Neurosci. Ther. 23, 554–566. doi: 10.1111/cns.12703
Feng, Y., Liu, T., Li, X. Q., Liu, Y., Zhu, X. Y., Jankovic, J., et al. (2014). Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson’s disease. Neurosci. Lett. 579, 35–40. doi: 10.1016/j.neulet.2014.07.014
Füllgrabe, J., Klionsky, D. J., and Joseph, B. (2013). Histone post-translational modifications regulate autophagy flux and outcome. Autophagy 9, 1621–1623. doi: 10.4161/auto.25803
Gan-Or, Z., Dion, P. A., and Rouleau, G. A. (2015). Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy 11, 1443–1457. doi: 10.1080/15548627.2015.1067364
Harada, S., Fujita-Hamabe, W., and Tokuyama, S. (2011). Effect of orexin-A on post-ischemic glucose intolerance and neuronal damage. J. Pharmacol. Sci. 115, 155–163. doi: 10.1254/jphs.10264FP
He, Y., Wan, S., Hua, Y., Keep, R. F., and Xi, G. (2008). Autophagy after experimental intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 28, 897–905. doi: 10.1038/sj.jcbfm.9600578
Hu, X., Tao, C., Gan, Q., Zheng, J., Li, H., and You, C. (2016). Oxidative stress in intracerebral hemorrhage: Sources, mechanisms, and therapeutic targets. Oxid. Med. Cell Longev. 2016:3215391. doi: 10.1155/2016/3215391
Irving, E. A., Harrison, D. C., Babbs, A. J., Mayes, A. C., Campbell, C. A., Hunter, A. J., et al. (2002). Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat. Neurosci. Lett. 324, 53–56. doi: 10.1016/s0304-3940(02)00176-3
Jiang, B., Li, Y., Dai, W., Wu, A., Wu, H., and Mao, D. (2021). Hydrogen-rich saline alleviates early brain injury through regulating of ER stress and autophagy after experimental subarachnoid hemorrhage. Acta Cir. Bras. 36:e360804. doi: 10.1590/ACB360804
Jing, C. h., Wang, L., Liu, P. p., Wu, C., Ruan, D., and Chen, G. (2012). Autophagy activation is associated with neuroprotection against apoptosis via a mitochondrial pathway in a rat model of subarachnoid hemorrhage. Neuroscience 213, 144–153. doi: 10.1016/j.neuroscience.2012.03.055
Kang, M., and Yao, Y. (2019). Oligodendrocytes in intracerebral hemorrhage. CNS Neurosci. Therap. 25, 1075–1084. doi: 10.1111/cns.13193
Kim, J. H., Hong, S. K., Wu, P. K., Richards, A. L., Jackson, W. T., and Park, J. I. (2014). Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels. Exp. Cell Res. 327, 340–352. doi: 10.1016/j.yexcr.2014.08.001
Kim, Y. J., Baek, E., Lee, J. S., and Lee, G. M. (2013). Autophagy and its implication in Chinese hamster ovary cell culture. Biotechnol. Lett. 35, 1753–1763. doi: 10.1007/s10529-013-1276-5
Kim-Han, J. S., Kopp, S. J., Dugan, L. L., and Diringer, M. N. (2006). Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke 37, 2457–2462. doi: 10.1161/01.STR.0000240674.99945.4e
Kitamura, E., Hamada, J., Kanazawa, N., Yonekura, J., Masuda, R., Sakai, F., et al. (2010). The effect of orexin-A on the pathological mechanism in the rat focal cerebral ischemia. Neurosci. Res. 68, 154–157. doi: 10.1016/j.neures.2010.06.010
Kotoda, M., Furukawa, H., Miyamoto, T., Korai, M., Shikata, F., Kuwabara, A., et al. (2018). Role of myeloid lineage cell autophagy in ischemic brain injury. Stroke 49, 1488–1495. doi: 10.1161/strokeaha.117.018637
Krafft, P. R., Altay, O., Rolland, W. B., Duris, K., Lekic, T., Tang, J., et al. (2012). α7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3β inhibition in a mouse model of intracerebral hemorrhage. Stroke 43, 844–850. doi: 10.1161/strokeaha.111.639989
Kyriakakis, E., Frismantiene, A., Dasen, B., Pfaff, D., Rivero, O., Lesch, K. P., et al. (2017). T-cadherin promotes autophagy and survival in vascular smooth muscle cells through MEK1/2/Erk1/2 axis activation. Cell Signal. 35, 163–175. doi: 10.1016/j.cellsig.2017.04.004
Laplante, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell 149, 274–293. doi: 10.1016/j.cell.2012.03.017
Li, H., Wu, J., Shen, H., Yao, X., Liu, C., Pianta, S., et al. (2018). Autophagy in hemorrhagic stroke: Mechanisms and clinical implications. Prog. Neurobiol. 163–164, 79–97. doi: 10.1016/j.pneurobio.2017.04.002
Li, T., Xu, W., Ouyang, J., Lu, X., Sherchan, P., Lenahan, C., et al. (2020). Orexin A alleviates neuroinflammation via OXR2/CaMKKbeta/AMPK signaling pathway after ICH in mice. J. Neuroinflammation 17:187. doi: 10.1186/s12974-020-01841-1
Li, W. D., Zhou, D. M., Sun, L. L., Xiao, L., Liu, Z., Zhou, M., et al. (2018). LncRNA WTAPP1 promotes migration and angiogenesis of endothelial progenitor cells via MMP1 through MicroRNA 3120 and Akt/PI3K/autophagy pathways. Stem Cells 36, 1863–1874. doi: 10.1002/stem.2904
Manaenko, A., Fathali, N., Khatibi, N. H., Lekic, T., Hasegawa, Y., Martin, R., et al. (2011). Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem. Int. 58, 542–548. doi: 10.1016/j.neuint.2011.01.018
Mohammad Ahmadi Soleimani, S., Azizi, H., Mirnajafi-Zadeh, J., and Semnanian, S. (2015). Orexin type 1 receptor antagonism in rat locus coeruleus prevents the analgesic effect of intra-LC met-enkephalin microinjection. Pharmacol. Biochem. Behav. 136, 102–106. doi: 10.1016/j.pbb.2015.07.010
Mracsko, E., and Veltkamp, R. (2014). Neuroinflammation after intracerebral hemorrhage. Front. Cell Neurosci. 8:388. doi: 10.3389/fncel.2014.00388
Nakamachi, T., Endo, S., Ohtaki, H., Yin, L., Kenji, D., Kudo, Y., et al. (2005). Orexin-1 receptor expression after global ischemia in mice. Regul. Pept. 126, 49–54. doi: 10.1016/j.regpep.2004.08.037
Ning, J., Junyi, T., Chang, M., Yueting, W., Jingyan, Z., Jin, Z., et al. (2019). TOM7 silencing exacerbates focal cerebral ischemia injury in rat by targeting PINK1/Beclin1-mediated autophagy. Behav. Brain Res. 360, 113–119. doi: 10.1016/j.bbr.2018.11.031
Ouyang, L., Shi, Z., Zhao, S., Wang, F. T., Zhou, T. T., Liu, B., et al. (2012). Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45, 487–498. doi: 10.1111/j.1365-2184.2012.00845.x
Rami, A., Langhagen, A., and Steiger, S. (2008). Focal cerebral ischemia induces upregulation of Beclin 1 and autophagy-like cell death. Neurobiol. Dis. 29, 132–141. doi: 10.1016/j.nbd.2007.08.005
Salminen, A., Kaarniranta, K., Kauppinen, A., Ojala, J., Haapasalo, A., Soininen, H., et al. (2013). Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Beclin 1 interactome. Prog. Neurobiol. 10, 33–54. doi: 10.1016/j.pneurobio.2013.06.002
Scammell, T. E., and Winrow, C. J. (2011). Orexin receptors: Pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 51, 243–266. doi: 10.1146/annurev-pharmtox-010510-100528
Shen, X., Ma, L., Dong, W., Wu, Q., Gao, Y., Luo, C., et al. (2016). Autophagy regulates intracerebral hemorrhage induced neural damage via apoptosis and NF-κB pathway. Neurochem. Int. 96, 100–112. doi: 10.1016/j.neuint.2016.03.004
Vergadi, E., Ieronymaki, E., Lyroni, K., Vaporidi, K., and Tsatsanis, C. (2017). Akt signaling pathway in macrophage activation and M1/M2 polarization. J. Immunol. 198, 1006–1014. doi: 10.4049/jimmunol.1601515
Wang, C., Wang, Q., Ji, B., Pan, Y., Xu, C., Cheng, B., et al. (2018). The orexin/receptor system: Molecular mechanism and therapeutic potential for neurological diseases. Front. Mol. Neurosci. 11:220. doi: 10.3389/fnmol.2018.00220
Wellnitz, K., and Taegtmeyer, H. (2010). Mechanical unloading of the failing heart exposes the dynamic nature of autophagy. Autophagy 6, 155–156. doi: 10.4161/auto.6.1.10538
Wen, J., Zhao, Y., and Guo, L. (2016). Orexin A induces autophagy in HCT-116 human colon cancer cells through the ERK signaling pathway. Int. J. Mol. Med. 37, 126–132. doi: 10.3892/ijmm.2015.2409
Wirawan, E., Vanden Berghe, T., Lippens, S., Agostinis, P., and Vandenabeele, P. (2012). Autophagy: For better or for worse. Cell Res. 22, 43–61.
Wu, C., Yan, X., Liao, Y., Liao, L., Huang, S., Zuo, Q., et al. (2019). Increased perihematomal neuron autophagy and plasma thrombin-antithrombin levels in patients with intracerebral hemorrhage: An observational study. Medicine (Baltimore) 98:e17130. doi: 10.1097/MD.0000000000017130
Wu, Y., Wang, L., Hu, K., Yu, C., Zhu, Y., Zhang, S., et al. (2018). Mechanisms and therapeutic targets of depression after intracerebral hemorrhage. Front. Psychiatry 9:682. doi: 10.3389/fpsyt.2018.00682
Xi, T., Jin, F., Zhu, Y., Wang, J., Tang, L., Wang, Y., et al. (2018). miR-27a-3p protects against blood-brain barrier disruption and brain injury after intracerebral hemorrhage by targeting endothelial aquaporin-11. J. Biol. Chem. 293, 20041–20050. doi: 10.1074/jbc.RA118.001858
Xu, D., Kong, T., Zhang, S., Cheng, B., Chen, J., and Wang, C. (2021). Orexin-A protects against cerebral ischemia-reperfusion injury by inhibiting excessive autophagy through OX1R-mediated MAPK/ERK/mTOR pathway. Cell Signal. 79:109839. doi: 10.1016/j.cellsig.2020.109839
Yang, G., Qian, C., Zhang, C., Bao, Y., Liu, M. Y., Jiang, F., et al. (2021). Hepcidin attenuates the iron-mediated secondary neuronal injury after intracerebral hemorrhage in rats. Transl. Res. 229, 53–68. doi: 10.1016/j.trsl.2020.09.002
Yiu, S. P. T., Hui, K. F., Choi, C. K., Kao, R. Y. T., Ma, C. W., Yang, D., et al. (2018). Intracellular iron chelation by a novel compound, C7, reactivates epstein-barr virus (EBV) lytic cycle via the ERK-autophagy axis in EBV-positive epithelial cancers. Cancers (Basel) 10, 505. doi: 10.3390/cancers10120505
Yu, S., Yu, M., He, X., Wen, L., Bu, Z., and Feng, J. (2019). KCNQ1OT1 promotes autophagy by regulating miR-200a/FOXO3/ATG7 pathway in cerebral ischemic stroke. Aging Cell 18:e12940. doi: 10.1111/acel.12940
Yuan, B., Shen, H., Lin, L., Su, T., Zhong, L., and Yang, Z. (2017). Autophagy promotes microglia activation through beclin-1-Atg5 pathway in intracerebral hemorrhage. Mol. Neurobiol. 54, 115–124. doi: 10.1007/s12035-015-9642-z
Yuan, L. B., Dong, H. L., Zhang, H. P., Zhao, R. N., Gong, G., Chen, X. M., et al. (2011). Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat. Anesthesiology 114, 340–354. doi: 10.1097/ALN.0b013e318206ff6f
Zhang, Y., and Liu, C. (2020). Autophagy and hemorrhagic stroke. Adv. Exp. Med. Biol 1207, 135–147. doi: 10.1007/978-981-15-4272-5_8
Zhao, H., Chen, Y., and Feng, H. (2018). P2X7 receptor-associated programmed cell death in the pathophysiology of hemorrhagic stroke. Curr. Neuropharmacol. 16, 1282–1295. doi: 10.2174/1570159X16666180516094500
Zhao, M., Gao, J., Cui, C., Zhang, Y., Jiang, X., and Cui, J. (2021). Inhibition of PTEN ameliorates secondary hippocampal injury and cognitive deficits after intracerebral hemorrhage: Involvement of AKT/FoxO3a/ATG-mediated autophagy. Oxid. Med. Cell Longev. 2021:5472605. doi: 10.1155/2021/5472605
Zhao, X. R., Gonzales, N., and Aronowski, J. (2015). Pleiotropic role of PPARgamma in intracerebral hemorrhage: An intricate system involving Nrf2, RXR, and NF-kappaB. CNS Neurosci. Ther. 21, 357–366. doi: 10.1111/cns.12350
Keywords: orexin A, autophagy, intracerebral hemorrhage, neuroprotection, orexin receptor
Citation: Zhang D, Cui Y, Zhao M, Zheng X, Li C, Wei J, Wang K and Cui J (2022) Orexin-A exerts neuroprotective effect in experimental intracerebral hemorrhage by suppressing autophagy via OXR1-mediated ERK/mTOR signaling pathway. Front. Cell. Neurosci. 16:1045034. doi: 10.3389/fncel.2022.1045034
Received: 15 September 2022; Accepted: 02 December 2022;
Published: 22 December 2022.
Edited by:
Ludovic Martin, Université Paris-Est Créteil Val de Marne, FranceCopyright © 2022 Zhang, Cui, Zhao, Zheng, Li, Wei, Wang and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jianzhong Cui, ✉ cuijianzhong1962@163.com